Details

Autor(en) / Beteiligte

• Roubelat, François-Philippe
• Barioulet, Lisa
• Varenne, Fanny
• Escudier, Clément
• Meyer, Pauline
• Gomane, Clément
• Butterworth, Jacqueline
• Pagot-Mathis, Véronique
• Fournié, Pierre
• Gualino, Vincent
• Soler, Vincent

Titel

The Reinforced Treat-and-Extend Protocol for Exudative Age-Related Macular Degeneration: Retrospective Assessment of 24-Month Real-World Outcomes in France

Ist Teil von

• Ophthalmology and therapy, 2024-06, Vol.13 (6), p.1647-1667

Ort / Verlag

Cheshire: Springer Healthcare

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Nexis

Beschreibungen/Notizen

• Introduction The aim of this work is to evaluate the real-world outcomes of the reinforced treat-and-extend (RTE) protocol for the treatment of exudative age-related macular degeneration with intravitreal injections of aflibercept or ranibizumab (anti-vascular endothelial growth factor therapies). Methods This was a retrospective review of patients from two tertiary ophthalmology centers in France initiating the RTE protocol between February 2018 and June 2021. The primary outcome was change in best-corrected visual acuity (BCVA) after 24 months. Secondary outcomes were change in central retinal thickness (CRT), recurrence, and management-related factors (injection interval, number of injections/consultations). Outcomes were additionally evaluated after protocol changes (strict versus modified RTE protocol groups). Results Sixty-eight patients (72 eyes) were included (68% females; mean age 82.2 ± 7.8 years). After 24 months, mean BCVA significantly improved (65.22 ± 14 vs. 71.96 ± 13 Early Treatment Diabetic Retinopathy Study letters; p  < 0.001) and CRT significantly decreased (388.6 ± 104 vs. 278.8 ± 51 μM; p  < 0.001) with 21% of eyes showing signs of exudation. Over the 24 months, a mean total of 14.9 ± 4.0 injections and 8.6 ± 1.4 consultations were performed. Mean 24-month injection interval was 7.9 ± 2.3 weeks. Initial and 24-month ophthalmic outcomes for eyes in the strict (47%) versus modified (53%) groups were not significantly different, but mean time interval to first recurrence of disease activity was significantly shorter for the modified group (7.3 ± 2.4 vs. 9.9 ± 2.5 weeks; p  < 0.001). Patients in the strict RTE group received significantly less injections (13.9 ± 3.6 vs. 16.5 ± 3.9; p  = 0.006) and mean 24-month injection interval was significantly longer (9.5 ± 2.7 vs. 6.5 ± 2.1 weeks; p  < 0.001). Consultation number was similar (8.5 ± 1.9 vs. 8.8 ± 1.6; p  = 0.93). Treatment with aflibercept versus ranibizumab did not influence ophthalmic or management outcomes. Conclusions The RTE protocol, even when modified, reduced consultations but improved ophthalmic outcomes. The RTE protocol could reduce hospital visits and overall burden while also encouraging better patient compliance. Video Abstract available for this article. 87UXnuCLS6rE_gv6c9Xvtc VIDEO ABSTRACT: Vincent Soler and François-Philippe Roubelat summarize the Reinforced Treat-and-Extend Protocol and main results (MP4 225022 KB)